The Role of Glutamate in the Control of Food Intake

谷氨酸在控制食物摄入量中的作用

基本信息

  • 批准号:
    8370480
  • 负责人:
  • 金额:
    $ 32.37万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1998
  • 资助国家:
    美国
  • 起止时间:
    1998-08-01 至 2017-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The gastrointestinal (GI) tract informs the brain of the quantity and quality of food consumed during meals. Hence, GI signals drive satiation, and are seminal to control of food intake, regardless of the conditions that initiate it. This application or renewal continues an enduring interest in neural mechanisms by which satiation signals are communicated to the hindbrain nucleus of the solitary tract (NTS) and integrated with other controls of food intake. Glutamate is the principal neurotransmitter released by vagal afferent terminals in the NTS. As such, glutamate receptors in the NTS are pivotal to the transmission and processing of vagal satiation signals. Our prior investigations revealed that activation of NMDA-type glutamate receptors in the NTS participate in control of meal size. Moreover, delay of meal termination by NTS injection of NMDAr antagonists depends on intact vagal afferent terminals in the NTS. Finally, activation NMDAr in the NTS is required for CCK-evoked MAPK signaling and consequent reduction of food intake by cholecystokinin (CCK), the archetypical GI satiation peptide. Nevertheless, we remain ignorant of the specific mechanisms by which NMDAr enable CCK- induced reduction of food intake. Therefore, one aim of this application is to use multiple in vivo and ex vivo preparations to test the nested hypotheses that reduction of food intake by CCK requires NMDAr-dependent activation of MAPK signaling in vagal afferent terminals in the NTS; that MAPK signaling results in pERK1/2- mediated phosphorylation of synapsin 1 in vagal afferent terminals; and leads to strengthened vagal afferent synaptic function in the NTS with consequent reduction of food intake. Other investigators have reported that hindbrain melanocortin receptor activation (MC4r) contributes to CCK-evoked MAPK signaling in the hindbrain and reduction of food intake. This report, taken together with our findings that NTS NMDAr activation is necessary for reduction of feeding by CCK, suggests an important interaction between NTS MC4r and NMDAr in control of food intake. Therefore, the second aim of this application is to establish a basic relationship between NTS NMDAr and MC4r that makes both crucial for CCK-induced reduction of food intake. Specifically we will apply pharmacological and immunochemical methods to determine whether NTS NMDAr activation is functionally upstream or downstream of NTS MC4r in control of food intake by CCK. In addition we will assess the possibility that NTS NMDAr participate in control of food intake by endogenous MC4r ligands in the NTS, and thereby may participate in the integration of melanocortinergic controls of food intake with those arising from vagal afferent activation. Our long-term goal is to determine how the unique properties of NMDAr contribute to the process of satiation and integration of GI satiation signals with other controls of food intake. Detailed appreciation of NTS NMDAr contributions to control of food intake is of significance to human health because it may provide avenues for therapeutic intervention in eating disorders and obesity. PUBLIC HEALTH RELEVANCE: Glutamate is the principal neurotransmitter released by vagal afferent neurons, which communicate information from the GI tract to the hindbrain. The NMDA-type glutamate receptor participates in the control of food intake by GI signals in the hindbrain. The proposed work will delineate the neural mechanisms by which hindbrain NMDA receptors contribute to the processes that reduce food intake, and determine how these receptors interact with other hindbrain receptors involved in control of food intake. Results will provide new insights into the process of satiation and potential points for therapeutic intervention in eating disorders and development of obesity.
描述(由申请人提供):胃肠道(GI)告知大脑进餐时消耗的食物的数量和质量。因此,胃肠道信号会驱动饱腹感,并且对于控制食物摄入量至关重要,无论引发它的条件如何。这种应用或更新延续了人们对神经机制的持久兴趣,通过这种机制将饱足信号传递到孤束的后脑核(NTS)并与其他食物摄入控制相结合。谷氨酸是 NTS 迷走神经传入末梢释放的主要神经递质。因此,NTS 中的谷氨酸受体对于迷走神经饱足信号的传输和处理至关重要。我们之前的研究表明,NTS 中 NMDA 型谷氨酸受体的激活参与了膳食量的控制。此外,NTS 注射 NMDAr 拮抗剂延迟进餐终止取决于 NTS 中完整的迷走神经传入末梢。最后,CCK 诱发的 MAPK 信号传导需要激活 NTS 中的 NMDAr,并随后通过缩胆囊素 (CCK)(典型的胃肠道饱足肽)减少食物摄入。然而,我们仍然不知道 NMDAr 使 CCK 诱导的食物摄入量减少的具体机制。因此,本申请的一个目的是使用多种体内和离体制剂来测试嵌套假设,即 CCK 减少食物摄入需要 NTS 迷走神经传入末梢中 MAPK 信号的 NMDAr 依赖性激活; MAPK 信号传导导致迷走神经传入末梢 pERK1/2 介导的突触蛋白 1 磷酸化;并导致 NTS 中迷走神经传入突触功能增强,从而减少食物摄入。其他研究人员报告称,后脑黑皮质素受体激活 (MC4r) 有助于后脑中 CCK 诱发的 MAPK 信号传导并减少食物摄入。该报告与我们的研究结果(NTS NMDAr 激活对于减少 CCK 摄食是必要的)相结合,表明 NTS MC4r 和 NMDAr 在控制食物摄入方面存在重要的相互作用。因此,该应用的第二个目标是建立 NTS NMDAr 和 MC4r 之间的基本关系,这使得两者对于 CCK 诱导的食物摄入减少至关重要。具体来说,我们将应用药理学和免疫化学方法来确定 NTS NMDAr 激活在功能上是 NTS MC4r 的上游还是下游,以控制 CCK 的食物摄入。此外,我们将评估 NTS NMDAr 参与 NTS 中内源性 MC4r 配体控制食物摄入的可能性,从而可能参与黑皮质素能食物摄入控制与迷走神经传入激活引起的食物摄入控制的整合。我们的 长期目标是确定 NMDAr 的独特特性如何促进饱足过程以及胃肠道饱足信号与其他食物摄入控制的整合。详细了解 NTS NMDAr 对控制食物摄入的贡献对人类健康具有重要意义,因为它可能为饮食失调和肥胖症的治疗干预提供途径。 公共健康相关性:谷氨酸是迷走神经传入神经元释放的主要神经递质,其将信息从胃肠道传递到后脑。 NMDA 型谷氨酸受体通过后脑中的胃肠道信号参与食物摄入的控制。拟议的工作将描述后脑 NMDA 受体参与减少食物摄入过程的神经机制,并确定这些受体如何与参与控制食物摄入的其他后脑受体相互作用。结果将为饱足过程提供新的见解,并为饮食失调和肥胖的发展提供治疗干预的潜在要点。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Robert C Ritter其他文献

Diet-Induced Cholecystokinin Release in Cats
  • DOI:
    10.1093/jn/124.suppl_12.2670s
  • 发表时间:
    1994-12-01
  • 期刊:
  • 影响因子:
  • 作者:
    Claudia A Kirk;J Lee Beverly;Robert C Ritter;Marcie J Strieker;Lynne Brenner;James G Morris;Quinton R Rogers
  • 通讯作者:
    Quinton R Rogers

Robert C Ritter的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Robert C Ritter', 18)}}的其他基金

The Role of Glutamate in the Control of Food Intake
谷氨酸在控制食物摄入量中的作用
  • 批准号:
    8868099
  • 财政年份:
    1998
  • 资助金额:
    $ 32.37万
  • 项目类别:
The Role of Glutamate in the Control of Food Intake
谷氨酸在控制食物摄入量中的作用
  • 批准号:
    7893251
  • 财政年份:
    1998
  • 资助金额:
    $ 32.37万
  • 项目类别:
The Role of Glutamate in the Control of Food Intake
谷氨酸在控制食物摄入量中的作用
  • 批准号:
    7177705
  • 财政年份:
    1998
  • 资助金额:
    $ 32.37万
  • 项目类别:
The Role of Glutamate in the Control of Food Intake
谷氨酸在控制食物摄入量中的作用
  • 批准号:
    8492068
  • 财政年份:
    1998
  • 资助金额:
    $ 32.37万
  • 项目类别:
The Role of Glutamate in the Control of Food Intake
谷氨酸在控制食物摄入量中的作用
  • 批准号:
    7516716
  • 财政年份:
    1998
  • 资助金额:
    $ 32.37万
  • 项目类别:
The Role of Glutamate in the Control of Food Intake
谷氨酸在控制食物摄入量中的作用
  • 批准号:
    7629009
  • 财政年份:
    1998
  • 资助金额:
    $ 32.37万
  • 项目类别:
The Role of Glutamate in the Control of Food Intake
谷氨酸在控制食物摄入量中的作用
  • 批准号:
    8668925
  • 财政年份:
    1998
  • 资助金额:
    $ 32.37万
  • 项目类别:
The Role of Glutamate in the Control of Food Intake
谷氨酸在控制食物摄入量中的作用
  • 批准号:
    8102906
  • 财政年份:
    1998
  • 资助金额:
    $ 32.37万
  • 项目类别:
ENTERIC CCK-NEURONS--VAGAL SYNAPSES AND CHEMORESPONSES
肠 CCK 神经元——迷走神经突触和化学反应
  • 批准号:
    2292530
  • 财政年份:
    1994
  • 资助金额:
    $ 32.37万
  • 项目类别:
ETHANOL AND INTESTINAL CONTROLS OF FOOD INTAKE
乙醇和肠道对食物摄入的控制
  • 批准号:
    3421989
  • 财政年份:
    1989
  • 资助金额:
    $ 32.37万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 32.37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 32.37万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 32.37万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 32.37万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 32.37万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 32.37万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 32.37万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 32.37万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 32.37万
  • 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
  • 批准号:
    10534864
  • 财政年份:
    2023
  • 资助金额:
    $ 32.37万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了